NDAORALTABLET
Approved
Mar 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIMINE (azatadine maleate) is an oral antihistamine tablet approved in 1977 by Merck & Co. for allergic conditions. It works as a first-generation H1-receptor antagonist to relieve allergy symptoms. The drug targets patients seeking symptomatic relief from allergies and related conditions.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%), signaling likely resource consolidation and team optimization for legacy brand management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
OPTIMINE roles focus on defending market share and optimizing profitability as exclusivity erodes, rather than growth or innovation. Career progression here emphasizes cost management, generic competition strategy, and portfolio rationalization skills applicable to legacy brand management.
Brand ManagerField Sales Representative
Worked on OPTIMINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.